Susan M. O’Brien, MD of University of California Irvine discusses Duvelisib and other PI3K inhibitors in CLL at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego.
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content